腎癌藥物市場：按類型、藥理學類別、治療層級- 全球預測 2023-2030

全球腎癌治療市場預計將大幅成長，到2023年將達到580213萬美元，年複合成長率為5.95%，預計到2030年將達到871012萬美元。

FPNV定位矩陣

FPNV 定位矩陣對於評估全球腎癌治療市場至關重要。透過檢驗業務策略和產品滿意度等關鍵指標，它可以對供應商進行全面評估，使用戶能夠根據自己的特定需求做出資訊的決策。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球腎癌藥物市場規模及預測為何？

2.在預測期內，COVID-19對全球腎癌治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球腎癌治療藥物市場需要投資哪些產品/細分市場/應用/領域？

4.你們在全球腎癌藥物市場的競爭策略是什麼？

5.全球腎癌藥物市場的技術趨勢和法律規範是什麼？

6.全球腎癌治療藥物市場主要廠商的市佔率為何？

7. 您認為哪些型態和策略性措施適合進入全球腎癌藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 罹癌的人數迅速增加
    • 患有高血壓和糖尿病的老年人口不斷增加
    • 增加生活方式的改變，例如吸煙、飲酒和吃加工食品
  • 抑制因素
    • 與治療相關的併發症的風險
  • 機會
    • 新藥的供應和強大的管道的存在
    • 透過製造商之​​間的合作增加研發投入
  • 任務
    • 嚴格的法規政策
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化
  • 管道分析

第6章 腎癌治療藥物市場：依類型

• 嫌色細胞
• 透明細胞
• 收集管
• 癌細胞
• 乳頭狀的

第7章 依藥理學類別分類的腎癌治療藥物市場

• 血管新生抑制劑
• 細胞激素免疫治療
• 單株抗體
• MTOR抑制劑

第8章 依治療類別分類的腎癌治療藥物市場

• 免疫療法
• 標靶治療

第9章 北美及南美腎癌藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太腎癌藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲腎癌藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Kidney Cancer Drugs Market is forecasted to grow significantly, with a projected USD 5,802.13 million in 2023 at a CAGR of 5.95% and expected to reach a staggering USD 8,710.12 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Kidney Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Kidney Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Chromophobe, Clear Cell, Collecting Duct, Oncocytic, and Papillary. The Collecting Duct is projected to witness significant market share during forecast period.

Based on Pharmacologic Class, market is studied across Angiogenesis Inhibitors, Cytokine Immunotherapy, Monoclonal Antibodies, and MTOR Inhibitors. The Monoclonal Antibodies is projected to witness significant market share during forecast period.

Based on Therapeutic Class, market is studied across Immunotherapy and Targeted Therapy. The Targeted Therapy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Kidney Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Kidney Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Kidney Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Kidney Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Kidney Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Kidney Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Kidney Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Kidney Cancer Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Kidney Cancer Drugs Market, by Type, 2022 vs 2030
• 4.3. Kidney Cancer Drugs Market, by Pharmacologic Class, 2022 vs 2030
• 4.4. Kidney Cancer Drugs Market, by Therapeutic Class, 2022 vs 2030
• 4.5. Kidney Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Proliferation in the number of people suffering from cancer
    • 5.1.1.2. Growing geriatric population with hypertension and diabetes
    • 5.1.1.3. Increasing lifestyle changes including smoking, drinking, and consumption of processed food
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of complications associated with treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Availability of novel drugs and the presence of a strong pipeline
    • 5.1.3.2. Increasing research and development investment coupled with collaborations among manufacturers
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory policies
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization
  • 5.9.1. Pipeline Analysis

6. Kidney Cancer Drugs Market, by Type

• 6.1. Introduction
• 6.2. Chromophobe
• 6.3. Clear Cell
• 6.4. Collecting Duct
• 6.5. Oncocytic
• 6.6. Papillary

7. Kidney Cancer Drugs Market, by Pharmacologic Class

• 7.1. Introduction
• 7.2. Angiogenesis Inhibitors
• 7.3. Cytokine Immunotherapy
• 7.4. Monoclonal Antibodies
• 7.5. MTOR Inhibitors

8. Kidney Cancer Drugs Market, by Therapeutic Class

• 8.1. Introduction
• 8.2. Immunotherapy
• 8.3. Targeted Therapy

9. Americas Kidney Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Kidney Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Kidney Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. KIDNEY CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. KIDNEY CANCER DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2022 VS 2030 (%)
• FIGURE 6. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2030 (%)
• FIGURE 7. KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. KIDNEY CANCER DRUGS MARKET DYNAMICS
• FIGURE 9. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. KIDNEY CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 11. KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY , BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 16. KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 28. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 45. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 48. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 100. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 112. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 115. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 145. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 146. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 147. KIDNEY CANCER DRUGS MARKET LICENSE & PRICING